Drugs, Investigational clinical trials
How each study uses Drugs, Investigational is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Drugs, Investigational studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 4
Novartis (2) · Pfizer (2) · EyeD Pharma (2) · Hasanuddin University (1) · University Children's Hospital Basel (1) · Chittagong Medical College (1) · Chinese PLA General Hospital (1) · Sun Pharmaceutical Industries Limited (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Drugs, Investigational.
- Dec 2026An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the FacePhase 1 · Sun Pharmaceutical Industries Limited
- Dec 2026Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal BurnsPhase 2 · Skingenix, Inc.
- Jan 2027Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract SurgeryPhase 1/2 · EyeD Pharma
- May 2027The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic SurgeryNot applicable · Chinese PLA General Hospital
Studies
Open first, then newest update. How each study uses Drugs, Investigational is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the FaceRecruitingPhase 1Sun Pharmaceutical Industries LimitedNCT07729579Written as Investigational drug
- Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract SurgeryRecruitingPhase 1/2EyeD PharmaNCT07036510Written as TimoD implant
- The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic SurgeryNot yet recruitingNot applicableChinese PLA General HospitalNCT07294755Written as Investigational drug 20 mL of 0.5% ropivacaine
- Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal BurnsRecruitingPhase 2Skingenix, Inc.NCT01297400Written as Investigational Drug, MW-III
- I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisActive, not recruitingNot applicableHasanuddin UniversityNCT07186478Written as Investigational Drug
- Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle GlaucomaTerminatedPhase 1EyeD PharmaNCT06321562Written as TimoD implant
- Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting ConditionsCompletedEarly Phase 1University Children's Hospital BaselNCT05477810Written as Treatment A (investigational drug) followed by Treatment B (reference drug)
- Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresCompletedPhase 2NovartisNCT01147003Written as Investigational new drug, company code: BGG492
- The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle GlaucomaCompletedPhase 2Chittagong Medical CollegeNCT04205201Written as Drugs, Investigational
- Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy SurgeryCompletedPhase 2NovartisNCT00887861Written as Investigational new drug, company code: BGG492
- A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal CancerTerminatedPhase 2Celgene CorporationNCT00040391Written as Investigational drug
- Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)CompletedPhase 2PfizerNCT00034957Written as Investigational drug
- The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's DiseaseTerminatedPhase 3Merck Sharp & Dohme LLCNCT00006187Written as Investigational drug
- Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple MyelomaCompletedPhase 1PfizerNCT00036140Written as Investigational drug
Codes
What other systems call Drugs, Investigational · ClinicalTrials.gg INT008471
- MeSH (NLM) D015507Drugs, InvestigationalOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015507 | Drugs, Investigational | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.